

Haematologica
HAEMATOL/2018/199257
Version 3

Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma

Renate De Smedt, Sofie Peirs, Julie Morscio, Filip Matthijssens, Juliette Roels, Lindy Reunes, Beatrice Lintermans, Steven Goossens, Tim Lammens, Nadine Van Roy, Aurore Touzart, Silvia Jenni, Yi-Chien Tsai, Federica Lovisa, Lara Mussolin, Valentina Serafin, Filip Van Nieuwerburgh, Dieter Deforce, Anne Uyttebroeck, Thomas Tousseyn, Birgit Burkhardt, Wolfram Klapper, Barbara De Moerloose, Yves Benoit, Elizabeth Macintyre, Jean-Pierre Bourquin, Giuseppe Basso, Benedetta Accordi, Beat Bornhauser, Jules Meijerink, Peter Vandenberghe, and Pieter Van Vlierberghe

Disclosures: The authours have nothing to disclose.

Contributions: RDS, SP, JM, AT, SJ, YT, FL, FM, LM and VS performed experiments. RDS, PVV, SJ and JR analyzed data. LR and BL provided technical assistance. FVN and DD performed RNA sequencing experiments. TL, NVR, AU, TT, BB, WK, BDM, YB and PV collected and provided primary T-ALL patient material. RDS, SG, EM, JPB, GB, BA, BB, JM and PVV designed research and wrote the paper, with help from the other authors. All authors have seen, reviewed and approved the final version of the manuscript.